These mutations alter DNA-binding capability of mutp53, concomitantly leading to a variable loss of p53 tumor suppressive functions, while mediating oncogenic GOF through transcriptional aberrations involving chromatin remodeling and interaction with transcription cofactors such as SREBP, ETS2, or NRF26,22,37,56. This evidence concerns the gene ETS2 and neoplasm.